Biologic drugs (bDMARD), especially TNF-α-inhibitors (TNFi), are used in refractory Takayasu's arteritis (TAK) patients. Up to 23% of patients are switched to a different bDMARD because of inefficacy. No data are available on which strategy is more efficient after TNFi failure. The aim of our study is to evaluate whether a switch or swap strategy should be preferred in TAK patients failing TNFis.
Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?
Malattia, Clara;Ravelli, Angelo;
2021-01-01
Abstract
Biologic drugs (bDMARD), especially TNF-α-inhibitors (TNFi), are used in refractory Takayasu's arteritis (TAK) patients. Up to 23% of patients are switched to a different bDMARD because of inefficacy. No data are available on which strategy is more efficient after TNFi failure. The aim of our study is to evaluate whether a switch or swap strategy should be preferred in TAK patients failing TNFis.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2021_Failure of.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
377.07 kB
Formato
Adobe PDF
|
377.07 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
